Dr. Lilit Karapetyan

Dr. Karapetyan’s clinical interest is in melanoma with the emphasis on cell therapy in advanced melanoma. Her clinical research is focused on investigating novel clinical trials of adoptive cell therapy employing ex vivo expanded tumor-infiltrating lymphocytes in patients with advanced melanoma. Dr Karapetyan’s translational research is focused on immunobiology of tertiary lymphoid structures (TLS) as these relate to melanoma progression, prognostic impact of TLE-related cytokines/chemokines and tumor elaborated factors associated with the development and maturation of TLS and the shaping of therapeutic anti-tumor immune responses in situ. She is a member of American Society of Clinical Oncology (ASCO), Society of Immunotherapy in Cancer (SITC), the recipient of an ASCO Young Investigator Award in 2022, and Melanoma Research Foundation Career Development Award in 2023.